New Report: IV Ibuprofen Market Is Estimated to Push Growth Margin to $14.2 Million, by 2022
"Adults end user segment accounted for major share in 2015, and is projected to maintain this trend throughout the forecast period. This is because the IV Ibuprofen was not prescribed for pediatrics until 2014. Pediatrics is projected to be the fastest growing end user segment, owing to the growing need for rapid pain and fever management in children (to avoid damage caused by inflammation and high body temperature) and increasing awareness about the use of IV Ibuprofen in children."
View full press release